Our findings in the LLC tumor model testify to the remarkable physiological plasticity of the mature TME, and identify potential strategies to reduce therapy resistance by targeting STING-responsive pathways that suppress antitumor immunity and inflammation. Here, STING1 is linked to neoplasm.